Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
Andre C KalilThomas F PattersonAneesh K MehtaKay M TomashekCameron R WolfeVarduhi GhazaryanVincent C MarconiGuillermo M Ruiz-PalaciosLanny HsiehSusan KlineVictor TapsonNicole M IovineMamta K JainDaniel A SweeneyHana M El SahlyAngela R BrancheJustino Regalado PinedaDavid C LyeUriel SandkovskyAnne F LuetkemeyerStuart H CohenRobert W FinbergPatrick E H JacksonBabafemi TaiwoCatharine I PaulesHenry ArguinchonaNathaniel ErdmannNeera AhujaMaria FrankMyoung-don OhEu-Suk KimSeow Yen TanRichard A MularskiHenrik NielsenPhilip O PonceBarbara S TaylorLuAnn LarsonNadine G RouphaelYoussef SaklawiValeria D CantosEmily R KoJohn J EngemannAlpesh N AminMiki WatanabeJoanne BillingsMarie-Carmelle ElieRichard T DaveyTimothy H BurgessJennifer FerreiraMichelle GreenMat MakowskiAnabela CardosoStephanie de BonoTyler BonnettMichael ProschanGregory A DeyeWalla DempseySeema U NayakLori E DoddJohn H Beigelnull nullPublished in: The New England journal of medicine (2020)
Baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation. The combination was associated with fewer serious adverse events. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT04401579.).